Navigation Links
Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals
Date:7/21/2011

logical bleeding and patients with a known serious hypersensitivity reaction (e.g., anaphylactic reaction or anaphylactic shock) to PRADAXA.

WARNINGS AND PRECAUTIONS

Risk of Bleeding

PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.

Risk factors for bleeding include:

- Medications that increase the risk of bleeding in general (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs).

-Labor and delivery

Promptly evaluate any signs or symptoms of blood loss, such as a drop in hemoglobin and/or hematocrit or hypotension. Discontinue PRADAXA in patients with active pathological bleeding.

Temporary Discontinuation of PRADAXA

Discontinuing PRADAXA for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of stroke.  Lapses in therapy should be avoided, and if PRADAXA must be temporarily discontinued for any reason, therapy should be restarted as soon as possible.

Effect of P-gp Inducers and Inhibitors on PRADAXA Exposure

The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces dabigatran exposure and should generally be avoided. P-gp inhibitors ketoconazole, verapamil, amiodarone, quinidine, and clarithromycin, do not require dose adjustments. These results should not be extrapolated to other P-gp inhibitors.

ADVERSE REACTIONS

In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in a higher rate of major GI bleeds and any GI bleeds compared to warfarin. In patients greater than or equal to 75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions.  These
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
2. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
5. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
6. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
7. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
8. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
9. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 27, 2015 According to the ... (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, Drug ... Europe , Asia-Pacific , Rest ... global biopreservation media market was valued at $247.7 million in ... by 2019, at a CAGR of 18.2% between 2014 and ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, Inc. ... 8,000 clinics have submitted over 100,000 specimens to IDEXX ... just the first 10 days since the breakthrough kidney ... (CKD) is a leading cause of suffering and death ... specimens are consistent with generally accepted kidney disease prevalence ...
(Date:7/25/2015)... ... , ... Technology leader Anton Paar offers the Abbemat ... temperature of the measuring prism. This is required to achieve the most precise ... key requirements. It is likely that no refractometer manufacturers on the market can ...
(Date:7/24/2015)... -- Equity Research Institute has initiated coverage ... PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... (NASDAQ: NWBO ), and Acorda Therapeutics Inc. (NASDAQ: ... can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI On Thursday, ... down 0.49%, the Dow Jones Industrial Average declined 0.67%, ...
Breaking Biology Technology:Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5It’s T-Time for Refractometers: On-site Temperature Check Now Available 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... , Revamilast is a PDE4 inhibitor, under development for ... successfully completed pre-clinical trials and Phase I studies , Phase ... UK , , Glenmark has initiated global  Phase IIb ... unmet medical need as globally they are over 300 million Asthma ...
... QinetiQ North America today announced the results of its ... experiment, which studied the effects of microgravity on host ... results of this experiment showed both the plants and ... (Biological Research In a Canister) homes on the shuttle. ...
... Bharat Renewable Energy Ltd (BREL) , a joint-venture of ... a program with SG Biofuels (SGB) to ... production of biodiesel in India. The program,s ... high performing hybrid varieties of Jatropha adapted to unique ...
Cached Biology Technology:Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 2Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 3Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast' 4QinetiQ North America Gains New Insights into Plant Growth and Sustainable Life Support on Final Shuttle Flight 2Bharat Renewable Energy Forms Alliance With SG Biofuels to Deploy Jatropha Hybrids for Biodiesel in India 2
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... body's natural immune responses could be a target of future cancer ... of Medicine of the University of Southern California. , The ... of Pathology, is the first to identify how EphB4 ?a protein ... important aspect of this study is that ?if we turn the ...
... uncovered a new cellular secret that may explain how ... cancers that makes treatment especially difficult. If the mechanism ... can be understood well enough to manipulate it, new ... metastatic cancers. , Significance of the Mayo Clinic ...
... potentially powerful new therapy for treating diabetes, peripheral vascular ... and into animals by demonstrating it restores nerve and ... particularly important implications for the estimated 21 million Americans ... blood vessels. , The therapy involves netrins, a family ...
Cached Biology News:USC researchers investigate protein that protects tumors 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 2Mayo Clinic researchers discover cancer cells may move via wave stimulation 3Proteins spur diabetic mice models to grow blood vessels, nerves 2